Cullinan Oncology - CGEM Income before deduction of interest, taxes and amortization

Graphic logo of cullinanoncology.com (CGEM)

Cullinan Therapeutics (CGEM) is a leading developer of targeted antibodies for the therapy of solid tumors. Monitoring EBITDA_Co via the GURU.Markets system chart demonstrates profit dynamics, where the 0.00 metric confirms the current level. Patent protection of unique molecules will provide the issuer with pricing power in the future, while strict laboratory control guarantees the environmental safety of bio-waste production.

Cullinan Therapeutics Inc - CGEM Operating profit EBITDA (period 11/23/2025 - 11/14/2026)

Cullinan Therapeutics, Inc. (CGEM) - metric breakdowns and financial figures

- market value and analyst target forecast:
Market Price Cullinan Corp|CGEM - Consensus Target
- issuer market value details:
Market Value Cullinan Therapeutics|CGEM - Real Price to Acquire Entire Company
- book capitalization information:
Book Price of a Share Cullinan Therapeutics|CGEM - Book Capitalization|Market Capitalization to Book Value Ratio cullinanoncology.com|CGEM - Aggregate Company Assets
- company total debt and liquidity indicators:
All Debt to Shareholders' Equity Ratio Cullinan Therapeutics|CGEM - Long-Term Debt to Capital|Short-Term Indebtedness to Equity Cullinan Oncology|CGEM - Company Aggregate Debts|Debts to Book Value Cullinan Therapeutics|CGEM - Company Long-Term Liabilities|Amount of Current Liabilities Cullinan Therapeutics|Immediate Liquidity cullinanoncology.com
- financial results and valuation multiples details:
CGEM - Net Profit|Net Profit Forecast Cullinan Therapeutics|CGEM - Price to Earnings Ratio|Future Price to Earnings Multiple cullinanoncology.com|CGEM - Price/Earnings to Growth Multiple|Enterprise Value to Operating Income Before Depreciation Ratio Cullinan Therapeutics|CGEM - Operating profit EBITDA|Earnings per share for the trailing year Cullinan Therapeutics|CGEM - Net earnings per share (EPS TTM)|Earnings per share growth in annualized terms for the last twelve months cullinanoncology.com|CGEM - Earnings per share growth in current year|Expected earnings per share trend next year Cullinan Therapeutics
- sales revenue and business income indicators:
CGEM - Revenue and Sales Volume|Projected Sales Volume Cullinan Corp|CGEM - Price-to-Revenue Ratio|Future Price to Revenue Cullinan Therapeutics
Summary company analytics:Cullinan Therapeutics
Brand item of Cullinan Therapeutics, Inc.

Cullinan Therapeutics (CGEM) is investing significant resources into proprietary modular oncology platforms, which necessitates strict cash flow management amid regulatory risks. The recorded EBITDA reflects the net cash result of daily operations excluding depreciation and amortization, allowing investors to assess the business's actual operational resilience and its ability to service its debt load.

Competitor analysis for Cullinan Therapeutics

Genmab Corp (GMAB) - Profit before interest, taxes and amortization|EXEL: Operating profit before deduction of amortization|Income before deduction of interest, taxes and amortization NUVL (nuvalent.com)|KYMR (Kymera) - Operating profit before deduction of amortization|IDYA: Company profit before taxes, interest and amortization|ELVN (Enliven Pharma) - Operating profit EBITDA|Operating profit EBITDA ORIC Corp|Profit before payment of interest, taxes and amortization Relay Therapeutics (RLAY)|NRIX (nurixtx.com) - Income before deduction of interest, taxes and amortization|Operating profit EBITDA TYRA (Tyra Biosciences)|Operating profit before depreciation charges Verastem Oncology|Monte Rosa Tx - Operating profit EBITDA|Profit before interest, taxes and amortization Immuneering Corp.|CCCC (C4 Therapeutics, Inc.) - Operating profit before deduction of amortization|BDTX: Company profit before taxes, interest and amortization|RPTX (Repare Therapeutics Inc.) - Operating profit EBITDA|Profit before interest, taxes and amortization PMV Pharmaceuticals Inc. PMVP|Operating profit EBITDA KPTI|propanc.com - Operating profit before amortization|Bio Green Med Solution Inc - Operating profit before deduction of amortization|Income before deduction of interest, taxes and amortization AADI|ALRN: Operating profit before deduction of amortization|Blueprint Medicines - Company profit before taxes, interest and amortization|GLYC: Operating profit EBITDA|SpringWorks Therapeutics, Inc - Income before deduction of interest, taxes and amortization